Aquarius Surgical Technologies (ASTI) AI Stock Analysis

• Market Cap: C$413.99K
• Dividend Yield: N/A
• Average Volume (3M): 6.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: -57.16%
• EPS Growth: 2.93%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.03
• Shares Outstanding: 27,599,173
• 10 Day Avg. Volume: 4,405
• 30 Day Avg. Volume: 6,901
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.10
• Price to Sales (P/S): 6.05
• P/FCF Ratio: -1.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.01 ▲(40.00% Upside)

The score is driven down primarily by poor financial performance (declining revenue, ongoing losses, negative equity, and negative cash flows). Technicals provide only partial support due to short-term strength but overbought RSI and weakness versus the 200-day average. Valuation does not offset the risk because the negative P/E reflects unprofitable operations and there is no dividend yield data.

Positive Factors

Product portfolio & market focus

A diversified portfolio across minimally invasive instruments, robotic systems and imaging aligns with long-term secular growth in less-invasive procedures. This breadth supports cross-selling, adoption by hospitals and sustained demand as procedures shift toward robotics and imaging-led care.

Recurring revenue streams

Recurring service, maintenance and training revenues provide durable revenue visibility and higher lifetime customer value, cushioning cyclical device sales. Over months this stabilizes cash inflows, supports aftermarket margins and strengthens commercial customer relationships.

Strategic partnerships and R&D collaborations

Partnerships with hospitals and research collaborations accelerate clinical validation, lower R&D risk and improve market access. Structurally, these alliances can shorten time-to-adoption for new devices, enhance credibility with clinicians, and reduce go-to-market costs over time.

Negative Factors

Revenue decline

A meaningful recent revenue decline undermines scale economics and weakens pricing leverage. Persisting top-line contraction erodes capacity to invest in R&D, sales and regulatory pathways, making it harder to regain market share and fund long-term product development.

Sustained unprofitability

Negative net and operating margins indicate structural operating inefficiencies or under-absorbed fixed costs. Continued losses impair reinvestment capacity, force reliance on external financing, and reduce flexibility to scale commercial operations or sustain long product development cycles.

Weak balance sheet

Negative shareholders' equity and high leverage create persistent solvency risk and constrain access to debt or equity on favorable terms. Over months this limits ability to fund operations, absorb setbacks, and execute on capital-intensive clinical trials or commercialization plans.

Aquarius Surgical Technologies Business Overview & Revenue Model

Company Description

Aquarius Surgical Technologies (ASTI) is a pioneering company in the medical device sector, specializing in advanced surgical solutions designed to enhance patient outcomes and streamline surgical procedures. The company focuses on developing innovative technologies for minimally invasive surgeries, including a range of surgical instruments, robotic systems, and imaging solutions that cater to various medical fields such as orthopedics, cardiology, and general surgery. ASTI is committed to improving surgical efficiency and safety through its cutting-edge products and comprehensive support services.

How the Company Makes Money

Aquarius Surgical Technologies generates revenue primarily through the sale of its surgical devices and instruments to hospitals, surgical centers, and healthcare providers. The company employs a direct sales model, supplemented by partnerships with industry distributors to expand its market reach. Key revenue streams include the sale of proprietary surgical instruments, robotic systems, and imaging technologies, as well as recurring income from service contracts, maintenance agreements, and training programs for healthcare professionals. Additionally, ASTI benefits from strategic alliances with healthcare institutions and participation in research collaborations, which can lead to the development of new products and technologies, further enhancing its revenue potential.

Aquarius Surgical Technologies Financial Statement Overview

Summary

Aquarius Surgical Technologies is facing significant financial challenges across all verticals. The income statement shows declining revenues and persistent losses, while the balance sheet reflects high leverage and negative equity. The cash flow statement indicates liquidity issues with negative cash flows. The company needs to address its operational inefficiencies and improve its financial stability to enhance its financial health.

Income Statement

Aquarius Surgical Technologies has experienced declining revenues with a negative revenue growth rate of -17.1% in the most recent year. The company also shows negative profit margins, with a net profit margin of -12.8%, indicating significant losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Overall, the income statement reveals financial struggles with declining revenues and persistent losses.

Balance Sheet

The balance sheet shows a concerning financial position with negative stockholders' equity, resulting in a negative debt-to-equity ratio. This indicates that liabilities exceed assets, posing a risk to financial stability. The return on equity is positive, but this is due to the negative equity base rather than profitability. Overall, the balance sheet reflects high leverage and financial instability.

Cash Flow

The cash flow statement shows negative operating and free cash flows, indicating cash outflows from operations. The free cash flow to net income ratio is 1.0, suggesting that cash flows are aligned with net losses. However, the negative operating cash flow coverage ratio highlights challenges in covering operational expenses. Overall, the cash flow statement reflects liquidity challenges and insufficient cash generation.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2023	Dec 2021	Dec 2021
Income Statement
Total Revenue	84.32K	91.20K	203.73K	205.25K	583.44K	327.66K
Gross Profit	45.38K	47.31K	81.91K	132.85K	216.59K	130.30K
EBITDA	126.17K	-832.81K	-517.35K	-456.62K	-1.34M	-611.35K
Net Income	-233.66K	-1.17M	-723.44K	-757.66K	-1.81M	-859.20K
Balance Sheet
Total Assets	2.83M	1.95M	680.14K	574.44K	946.13K	894.98K
Cash, Cash Equivalents and Short-Term Investments	14.28K	7.56K	122.02K	107.38K	145.97K	158.19K
Total Debt	6.58M	6.47M	3.51M	4.04M	2.93M	3.24M
Total Liabilities	7.89M	7.72M	4.53M	5.18M	3.34M	4.11M
Stockholders Equity	-5.06M	-5.77M	-3.85M	-4.61M	-2.39M	-3.21M
Cash Flow
Free Cash Flow	-371.23K	-383.29K	38.82K	-256.92K	-509.00K	-117.38K
Operating Cash Flow	-371.23K	-383.29K	38.82K	-252.56K	-450.52K	-112.16K
Investing Cash Flow	-1.80M	-1.80M	0.00	-4.36K	-100.00K	-5.22K
Financing Cash Flow	2.07M	2.08M	-75.00K	242.29K	591.30K	129.59K

Aquarius Surgical Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASTI, the sentiment is Positive. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 74.48 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ASTI.

Aquarius Surgical Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRN	55 Neutral	C$421.71M	-6.22	-127.60%	―	72.03%	-1.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VPT	50 Neutral	C$20.96M	-5.04	―	―	28.59%	23.46%
ASG	46 Neutral	C$21.07M	-11.16	-31.12%	―	9.71%	-118.02%
PINK	46 Neutral	C$36.16M	-1.62	-181.70%	―	209.29%	35.38%
ASTI	42 Neutral	C$413.99K	-0.50	―	―	-57.16%	2.93%